Study to Investigate the Receptor Occupancy of HTL0014242 Using [18F] FPEB in Healthy Male Subjects

  • STATUS
    Recruiting
  • participants needed
    10
  • sponsor
    Heptares Therapeutics Limited
Send
Updated on 16 February 2024
See if I qualify
electrocardiogram

Summary

A Study in Healthy Volunteers to Investigate How a New Drug for the Treatment of Parkinson's Disease, Dystonia and Amyotrophic Lateral Sclerosis Binds to Receptor Sites in the Brain.

Description

This is an open-label, single dose, adaptive study of orally adminstered HTL0014242 in up to 10 healthy male subjects. The primary objective is to investigate the pharmacokinetic-receptor occupancy relationship of single oral doses of HTL0014242 in healthy subjects. The secondary objectives are to assess the plasma pharmacokinetics (PK), safety and tolerability of single oral doses of HTL0014242 in healthy subjects.

Details
Condition Healthy
Age 23years - 55years
Treatment HTL0014242
Clinical Study IdentifierNCT04462263
SponsorHeptares Therapeutics Limited
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Healthy male, aged between 23 and 55 years inclusive, with body mass index between 18.5 and 32 kg/m2
Healthy on the basis of a clinical history, physical examination, electrocardiogram (ECG), vital signs and laboratory tests of blood and urine
Able to give fully informed consent and has suitable veins for cannulation and arterial access in both wrists
Resting BP and heart rate within normal ranges after 5 mins rest

Exclusion Criteria

Past, current or family history of mental, behavioural or neurodevelopmental disorder
Clinically significant history or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, pyschiatric disorders, metabolic, allergic, dermatological, haematological, pulmonary or respiratory disorder
History of significant hypersensitivity, intolerance or allergy to any drug compound, food or other substance, unless approved by Investigator
Active neoplastic disease or history of any neoplastic disease within 5 years of screening
Active infection (e.g sepsis, pneumonia, abscess) or serious infection (e.g resulting in hospitalisation or requiring parenteral antibiotic treatment) within 90 days prior to dosing
History of stomach or intestinal surgery or resection
Any of following at screening or pre-dose: QT internal heart rate correction; QRS duration >120ms; PR interval > 220ms; QTc measurements/data difficult or uninterpreable; history of additional risk factors for torsades de pointe
drug or alcohol abuse in last 2 years
Alcohol consumption is > 14 units per week
Positive Urine alcohol or drug tests
Positive HIV, Hep B, Hep C test
Aspartate aminotransferase, Alanine aminotransferase, Gamma glutamyl transferase, Alkaline phosphatase or total bilirubin above normal upper limits
Participation in other clinical trials of unlicensed medicines in the previous 3 months, or 7 half-lives of the medicine (whichever is longer)
Previously dosed with HTL0014242
Intention to use or using medications that interfere with drug absorption, metabolism or elimination processes incl St John's Wort, 30 days prior to dosing
Use of ketamine, amphetamines or MDMA with 9o days prior to dosing
Use or intend to use any prescription or non-prescription medications within 14 days or 5 half-lives of medication, prior to dosing. Investigator and study team to determine implications on safety or study procedures, on a case-by-case basis
Received live attenuated vaccination within 6 weeks prior to Screening, or intends to receive vaccination during the study
Smoker or user of tobacco- or nicotine-containing products
Receipt of blood products within 2 months prior to dosing. Donation of blood / comparable blood loss 3 months prior to dosing
Abnormal Allen's circulation test result. Evaluation of arterial access indicates risk of occlusion or insufficient supply. Evaluation of venous access indicates difficulties in obtaining venous blood
Subject unable or unwilling to abstain from alcohol or caffeine-containing foods and beverages. Significant consumption of any foods or beverages containing CYP1A2 inducers with 2 weeks prior to Admission (Investigator opinion)
Significant consumption of any foods or beverages containing Seville-type oranges, grapefruit, or poppy seeds within 7 days prior to baseline PET and admission (Investigator opinion)
Subject, in opinion of Investigator should not participate in this study. Reply from GP, for this specific study probing psychiatric history must be received before dosing
Participation in research study or other radiation exposure (e.g workplace) which in conjunction with this study will exceed ionisation radiation exposure over 10mSv within 12 months prior to the Screening visit
Contraindication for MRI, assessed by standard pre-MRI questionnaire, that preclude subject undergoing MRI scans
Subject suffers from claustrophobia (incapable of undergoing MRI or PET scan) or needle phobia
Subject has abnormal findings per structural MRI scan at screening
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

electrocardiogram

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.